51
|
Houivet E, Hebert V, Boulard C, Vaillant M, Duvert Lehembre S, Borradori L, Della Torre R, Feliciani C, Fania L, Zambruno G, Camaioni D, Didona B, Marinovic B, Schmidt E, Schumacher N, Hünefeld C, Schanz S, Johannes Steffen Kern J, Hofmann S, Bouyeure A, Picard-Dahan C, Prost-Squarcioni C, Caux F, Alexandre M, Ingen-Housz-Oro S, Bagot M, Tancrede-Bohin E, Bouaziz J, Franck N, Vabres P, Labeille B, Aleth Richard M, Delaporte E, Dupuy A, D’Incan M, Quereux G, Skowron F, Paul C, Bulai Livideanu C, Beylot-Barry M, Doutre M, Avenel-Audran M, Bedane C, Bernard P, Machet L, Maillard H, Jullien D, Debarbieux S, Sassolas B, Misery L, Abasq C, Dereure O, Lagoutte P, Ferranti V, Werth V, Murrell D, Hertl M, Benichou J, Joly P. Corrélation entre les scores de sévérité clinique (ABSIS, PDAI, PGA), la qualité de vie (DLQI) et les taux d’Ac anti-desmogléine 1 et 3 dans le suivi du pemphigus. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.048] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
52
|
Joly P, Houivet E, Prost C, Maho-Vaillant M, Picard Dahan C, Duvert Lehembre S, Labeille B, Richard M, Bernard P, Dupuy A, Bouaziz J, Oro S, Chosidow O, Vabres P, Delaporte E, Avenel M, Alexandre M, Caux F, Incan M, Bedane C, Quereux G, Machet L, Dereure O, Skowron F, Franck N, Beylot-Barry M, Doutre M, Beneton N, Debarbieux S, Jullien D, Misery L, Ferranti V, Benichou J, Musette P. Étude randomisée évaluant l’efficacité et la tolérance du rituximab associé à une corticothérapie allégée par rapport à une corticothérapie standard dans le traitement du pemphigus. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
53
|
Loget J, Plée J, Barbe C, Duvert-Lehembre S, Couraud A, Bedane C, Maizières M, Joly P, Bernard P. Évaluation de l’incidence et de la répartition des différentes dermatoses bulleuses auto-immunes dans 3 régions françaises par le registre REGIBUL (2010–2014). Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
54
|
Hurabielle C, Bedane C, Avenel-Audran M, Adamski H, Aubin F, Jeanmougin M, Marguery MC, Peyron JL, Poreaux C, Schmutz JL, Viguier M. No major effect of cyclosporin A in patients with severe solar urticaria: a french retrospective case series. Acta Derm Venereol 2015; 95:1030-1. [PMID: 26014373 DOI: 10.2340/00015555-2140] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
55
|
Jouary T, Kubica E, Dalle S, Pages C, Duval-Modeste AB, Guillot B, Mansard S, Saiag P, Aubin F, Bedane C, Dalac S, Dompmartin A, Granel-Brocard F, Lok C, Stoebner PE, Lacour JP, Leccia MT, Diallo A, Ezzedine K, Mateus C. Sentinel node status and immunosuppression: recurrence factors in localized Merkel cell carcinoma. Acta Derm Venereol 2015; 95:835-40. [PMID: 25784178 DOI: 10.2340/00015555-2099] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
The prognostic value of the sentinel lymph node in Merkel cell carcinoma (MCC) has been examined previously in heterogeneous retrospective studies. The current retrospective study included a homogeneous population of patients with a localized MCC, all staged with sentinel lymph node biopsy. Factors associated with 3-year progression-free survival were analysed using logistic regression. The sentinel lymph node was positive in 32% of patients. The recurrence rate was 26.9%. In first analyses (n = 108), gender (p = 0.0115) and the presence of immunosuppression (p = 0.0494) were the only significant independent factors. In further analyses (n = 80), excluding patients treated with regional radiotherapy, sentinel lymph node status was the only significant prognostic factor (p = 0.0281). Immunosuppression and positive sentinel lymph node are associated with a worse prognosis in patients with MCC. Nodal irradiation impacts on the prognostic value of the sentinel lymph node status.
Collapse
|
56
|
Plee J, Le Jan S, Giustiniani J, Barbe C, Joly P, Bedane C, Vabres P, Truchetet F, Aubin F, Antonicelli F, Bernard P. Étude prospective multicentrique du suivi des concentrations sériques d’IL-17 et d’IL-23 chez les malades atteints de pemphigoïde bulleuse. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.04.040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
57
|
Lesteven E, Battistella M, Jouary T, Dalac S, Dalle S, Guillot B, Arnault JP, Avril MF, Bedane C, Bens G, Beylot-Barry M, Grange F, Meyer N, Machet L, Saiag P, Dumaz N, Mourah S, Lebbe C. Phase II multicentric uncontrolled national trial assessing the efficacy of nilotinib in the treatment of advanced melanomas with c-KIT mutation or amplification: Results of the pharmacodynamic study. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.e20062] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
58
|
Aubin F, Porcher R, Jeanmougin M, Léonard F, Bedane C, Moreau A, Schmutz JL, Marguery MC, Adamski H, Viguier M. Efficacité et tolérance des immunoglobulines intraveineuses dans l’urticaire solaire et réfractaire : résultats d’une étude de phase II. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
59
|
Lubrano V, Derrey S, Truc G, Mirabel X, Thariat J, Cupissol D, Sassolas B, Combemale P, Modiano P, Bedane C, Dygai-Cochet I, Lamant L, Mourrégot A, Rougé Bugat MÈ, Siegrist S, Tiffet O, Mazeau-Woynar V, Verdoni L, Planchamp F, Leccia MT. [Locoregional treatments of brain metastases for patients with metastatic cutaneous melanoma: French national guidelines]. Neurochirurgie 2014; 60:269-75. [PMID: 25241016 DOI: 10.1016/j.neuchi.2014.05.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2013] [Revised: 05/12/2014] [Accepted: 05/21/2014] [Indexed: 11/22/2022]
Abstract
INTRODUCTION The management of metastatic cutaneous melanoma is changing, marked by innovative therapies. However, their respective use and place in the therapeutic strategy continue to be debated by healthcare professionals. OBJECTIVE The French national cancer institute has led a national clinical practice guideline project since 2008. It has carried out a review of these modalities of treatment and established recommendations. METHODS The clinical practice guidelines development process is based on systematic literature review and critical appraisal by experts. The recommendations are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines are reviewed by independent practitioners in cancer care delivery. RESULTS This article presents the results of bibliographic search, the conclusions of the literature and the recommendations concerning locoregional treatments of brain metastases for patients with metastatic cutaneous melanoma.
Collapse
|
60
|
Plee J, Le Jan S, Giustiniani J, Joly P, Bedane C, Vabres P, Truchetet F, Aubin F, Antonicelli F, Bernard P. Les profils évolutifs des taux sériques d’IL-17 et d’IL-23 permettent de prédire le risque de rechute de pemphigoïde bulleuse dans la première année de traitement. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
61
|
Prud’homme R, Bedane C, Couture M, Assikar S, Enescu C. Mélanome clitoridien métastatique muté KIT répondant à l’imatinib (Glivec®). Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
62
|
Hurabielle C, Bedane C, Avenel-Audran M, Adamski H, Aubin F, Jeanmougin M, Marguery MC, Peyron JL, Poreaux C, Schmutz JL, Viguier M. Efficacité et tolérance de la ciclosporine dans l’urticaire solaire : étude rétrospective multicentrique. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
63
|
Lebbé C, Chevret S, Jouary T, Dalac S, Guillot B, Dalle S, Arnaud JP, Avril M, Bedane C, Bens G, Beylot-Barry M, Mansart S, Grange F, Meyer N, Machet L, Misery L, Saiag P, Pages C, Battistella M, Mourah S, Dumaz N. Étude multicentrique de phase II non contrôlée évaluant l’intérêt du nilotinib dans le traitement des mélanomes avancés mutés ou amplifiés c-KIT. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
64
|
Lebbe C, Chevret S, Jouary T, Dalac S, Dalle S, Guillot B, Arnault JP, Avril MF, Bedane C, Bens G, Beylot-Barry M, Mansard S, Grange F, Meyer N, Machet L, Misery L, Saiag P, Battistella M, Mourah S, Dumaz N. Phase II multicentric uncontrolled national trial assessing the efficacy of nilotinib in the treatment of advanced melanomas with c-KIT mutation or amplification. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.9032] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
65
|
Cupissol D, Sassolas B, Combemale P, Modiano P, Bedane C, Derrey S, Dygai-Cochet I, Lamant L, Lubrano V, Mirabel X, Mourrégot A, Rougé Bugat ME, Siegrist S, Thariat J, Tiffet O, Truc G, Verdoni L, Mazeau-Woynar V, Planchamp F, Leccia MT. Traitements systémiques de première et de deuxième lignes des patients atteints d’un mélanome cutané métastatique (hors métastase cérébrale) : Recommandations nationales françaises. ONCOLOGIE 2014. [DOI: 10.1007/s10269-013-2360-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
66
|
Belyamani S, Hali F, Mernissi F, Zamiati S, Bedane C, Benchikhi H. [Bullous pemphigoid: Particular clinical and immuno-histological profil in a young woman]. Presse Med 2014; 43:471-3. [PMID: 24440766 DOI: 10.1016/j.lpm.2013.07.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/08/2013] [Revised: 07/27/2013] [Accepted: 07/31/2013] [Indexed: 11/29/2022] Open
|
67
|
Sassolas B, Mourrégot A, Thariat J, Tiffet O, Dygai-Cochet I, Mirabel X, Truc G, Cupissol D, Modiano P, Combemale P, Bedane C, Derrey S, Lamant L, Lubrano V, Siegrist S, Rougé-Bugat MÈ, Mazeau-Woynar V, Verdoni L, Planchamp F, Leccia MT. [Loco-regional treatments of the metastatic sites for patients with pauci-metastatic cutaneous melanoma (without brain metastasis): French national guidelines]. Bull Cancer 2014; 101:9-16. [PMID: 24369290 DOI: 10.1684/bdc.2013.1868] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
INTRODUCTION The last years are marked by the emergence of new molecules for the treatment of metastatic cutaneous melanoma with a significant benefit on the survival. Besides, some techniques are in development for the loco-regional treatment of the metastatic sites, bringing new therapeutic perspectives. However, their respective use and place in the therapeutic strategy are debated by healthcare professionals. OBJECTIVE The French National Cancer Institute leads a national clinical practice guidelines project since 2008. It realized a review of these modalities of treatment and developed recommendations. METHODS The clinical practice guidelines development process is based on systematic literature review and critical appraisal by a multidisciplinary expert workgroup. The recommendations are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines are reviewed by independent practitioners in cancer care delivery. RESULTS This article presents recommendations for loco-regional treatments of the pulmonary, bone, cutaneous, hepatic and digestive metastatic sites for patients with pauci-metastatic cutaneous melanoma.
Collapse
|
68
|
Konstantinou MP, Dutriaux C, Gaudy-Marqueste C, Mortier L, Bedane C, Girard C, Thellier S, Jouary T, Grob JJ, Richard MA, Templier C, Sakji L, Guillot B, Paul C, Meyer N. Ipilimumab in melanoma patients with brain metastasis: a retro-spective multicentre evaluation of thirty-eight patients. Acta Derm Venereol 2014; 94:45-9. [PMID: 23824275 DOI: 10.2340/00015555-1654] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Treatment with ipilimumab, a monoclonal antibody that antagonizes cytotoxic T-lymphocyte antigen-4 (CTLA-4), results in improved survival of patients with stage IIIc-IV melanoma. However, there is a lack of data on the efficacy of ipilimumab in patients with brain metastases. To evaluate the efficacy of ipilimumab for the treatment of brain metastasis in melanoma, a multicentre, retrospective analysis of 38 patients with brain metastases in melanoma, treated with ipilimumab in the context of the French Expanded Access Program, was performed. Three patients had a 3 partial response, 5 stable disease, 15 disease progression and 15 patients died during the induction phase due to disease progression. Median overall survival was 101 days (range 54-154). The brain metastases control rate was 16% (6/38). Ipilimumab may be effective in a few patients with central nervous system metastasis. However, patients with brain metastases and a low life expectancy may not benefit sufficiently from treatment with ipilimumab.
Collapse
|
69
|
Fichel F, Barbe C, Joly P, Bedane C, Vabres P, Truchetet F, Aubin F, Michel C, Jegou J, Grange F, Antonicelli F, Bernard P. Clinical and immunologic factors associated with bullous pemphigoid relapse during the first year of treatment: a multicenter, prospective study. JAMA Dermatol 2014; 150:25-33. [PMID: 24226428 DOI: 10.1001/jamadermatol.2013.5757] [Citation(s) in RCA: 60] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2023]
Abstract
IMPORTANCE Although predisposing factors for bullous pemphigoid (BP) have been recently established, no clinical or immunologic factors have yet been identified to predict disease outcome. OBJECTIVE To identify risk factors for BP relapse during the first year of treatment. DESIGN, SETTING, AND PARTICIPANTS Multicenter prospective study of 120 consecutive patients with newly diagnosed BP in 8 French dermatology departments. Baseline and 6 follow-up visits were planned to record disease activity and collect blood samples for measurement of serum anti-BP180 and anti-BP230 levels by means of enzyme-linked immunosorbent assay (ELISA). MAIN OUTCOMES AND MEASURES The end point was clinical relapse within the first year of therapy. Associations of clinical and immunologic (including serum levels of anti-BP180 and anti-BP230 autoantibodies) parameters with clinical relapse were assessed using univariate and multivariate analyses. RESULTS During the 1-year follow-up, 35 patients (29.2%) experienced relapse, whereas anti-BP180 and anti-BP230 ELISA results were similar at baseline between patients who did and did not experience relapse. Factors at baseline independently associated with relapse were extensive disease at inclusion (hazard ratio [HR], 2.37 [95% CI, 1.2-4.8]) and an associated dementia (HR, 2.09 [95% CI, 1.0-4.2]). Use of superpotent topical corticosteroids alone (by 100 patients [83.3%]) induced a dramatic, early decrease in serum levels of anti-BP180 and anti-BP230 autoantibodies. Mean early decreases in autoantibody levels between baseline and day 60 were lower in patients with relapse compared with patients with ongoing remission (-10.0% and -45.2%, respectively, for anti-BP180 levels [P < .001] and -11.8% and -35.4%, respectively, for anti-BP230 levels [P = .046]). A higher serum level of anti-BP180 at day 150, with a cutoff of 23 U/mL, provided 84.2% sensitivity, 44.8% specificity, 33.3% positive predictive value, and 89.7% negative predictive value for the occurrence of relapses between days 150 and 360. CONCLUSIONS AND RELEVANCE The pronounced decrease in the level of anti-BP180 autoantibodies and, to a lesser extent, those directed against BP230 confirmed the use of superpotent topical corticosteroids alone as a reference BP treatment. Furthermore, our study suggests that neurological diseases play a major role in BP, not only as a predisposing but also as a prognostic factor.
Collapse
|
70
|
Leccia MT, Planchamp F, Sassolas B, Combemale P, Modiano P, Bedane C, Cupissol D, Derrey S, Dygai-Cochet I, Lamant L, Lubrano V, Mirabel X, Mourrégot A, Rougé Bugat ME, Siegrist S, Thariat J, Tiffet O, Truc G, Verdoni L, Mazeau-Woynar V. [Management of patients with metastatic cutaneous melanoma: French national guidelines. French National Cancer Institute]. Ann Dermatol Venereol 2013; 141:111-21. [PMID: 24507205 DOI: 10.1016/j.annder.2013.10.055] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2013] [Accepted: 10/25/2013] [Indexed: 11/18/2022]
Abstract
BACKGROUND Recent years have seen the emergence of new molecules for the treatment of patients with metastatic cutaneous melanoma, with significant benefits in terms of survival and the opening of new therapeutic perspectives. In addition, many techniques are currently being developed for locoregional treatment of metastatic sites. Management of metastatic melanoma is thus fast-changing and is marked by innovative therapeutic approaches. However, the availability of these new treatments has prompted debate among healthcare professionals concerning their use and their place in therapeutic strategy. AIMS Since 2008, the French National Cancer Institute (INCa) has been leading a project to define and diffuse national clinical practice guidelines. It has performed a review of these treatment methods, which it aims to circulate, and it is seeking to develop recommendations in order to allow nationwide implementation of innovative approaches while promoting good use thereof. METHODS The clinical practice guidelines development process is based on systematic literature review and critical appraisal by experts within a multidisciplinary working group, with feedback from specialists in cancer care delivery. The recommendations are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines are reviewed by independent practitioners in cancer care delivery. RESULTS This article presents the national recommendations for first- and second-line systemic treatment and for locoregional treatment of metastatic sites in patients presenting metastatic cutaneous melanoma.
Collapse
|
71
|
Bernard P, Fichel F, Barbe C, Joly P, Bedane C, Vabres P, Truchetet F, Aubin F, Michel C, Jegou J, Grange F, Antonicelli F. Facteurs cliniques et immunologiques associés aux rechutes de pemphigoïde bulleuse dans la première année de traitement : étude multicentrique et prospective. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
72
|
Commin M, Prost C, Picard-Dahan C, Duvert-Lehembre S, Labeille B, Paul C, Richard M, Dalac S, Bernard P, Dupuy A, Bouaziz J, Oro SIH, Avenel M, Sassolas B, Alexandre M, Caux F, D’Incan M, Delaporte E, Bedane C, Quereux G, Machet L, Vabres P, Dereure O, Skowron F, Franck N, Barry MB, Maillard H, Debardieux S, Jullien D, Misery L, Ferranti V, Joly P. Analyse intermédiaire de l’efficacité du rituximab comme traitement de première intention du pemphigus. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
73
|
Boulard C, Bouyeure A, Houivet E, Borradori L, Huenefeld C, Schmidt E, Marinovic B, Zambruno G, Feliciani C, Prost C, Picard-Dahan C, Duvert Lehembre S, Labeille B, Paul C, Richard M, Dalac S, Bernard P, Dupuy A, Caux F, Bouaziz J, Oro S, Avenel-Audran M, Misery L, Sassolas B, Alexandre M, D’Incan M, Delaporte E, Bedane C, Quereux G, Machet L, Vabre P, Dereure O, Skowron F, Franck N, Beylot-Barry M, Beneton Benhard N, Debarbieux S, Jullien D, Benichou J, Ferranti V, Murrell D, Hertl M, Joly P. Qualité de vie chez les patients atteints de pemphigus : corrélation avec le type et la sévérité du pemphigus. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
74
|
Bertolotti A, Pham-Ledard AL, Vergier B, Parrens M, Bedane C, Beylot-Barry M. Lymphomatoid papulosis type D: an aggressive histology for an indolent disease. Br J Dermatol 2013; 169:1157-9. [DOI: 10.1111/bjd.12463] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
75
|
Almugairen N, Hospital V, Bedane C, Duvert-Lehembre S, Picard D, Tronquoy AF, Houivet E, D'incan M, Joly P. Assessment of the rate of long-term complete remission off therapy in patients with pemphigus treated with different regimens including medium- and high-dose corticosteroids. J Am Acad Dermatol 2013; 69:583-8. [DOI: 10.1016/j.jaad.2013.05.016] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2012] [Revised: 05/17/2013] [Accepted: 05/22/2013] [Indexed: 01/26/2023]
|